Ignite Creation Date:
2024-05-06 @ 2:50 AM
Last Modification Date:
2024-10-26 @ 11:24 AM
Study NCT ID:
NCT02135887
Status:
UNKNOWN
Last Update Posted:
2020-12-22
First Post:
2014-05-06
Brief Title:
A Trial of MB-6 for Reduction of Neutropenia Induced by Chemotherapy in Patients With Stage III Colorectal Cancer
Sponsor:
Microbio Co Ltd
Organization:
Microbio Co Ltd
Study Overview
Official Title:
The Purpose of This Study is to Evaluate the Effectiveness of MB-6 as Adjuvant Therapy in Reducing Neutropenia When Given Oxaliplatin-based Chemotherapy in Patients With Stage 3 Colorectal Cancer Previously Treated With Surgery
Status:
UNKNOWN
Status Verified Date:
2020-12
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MB-6
Brief Summary:
This is a randomized double-blind placebo-controlled multi-center phaseⅢstudy to evaluate efficacy and safety of oxaliplatin-based chemotherapy plus MB-6320 mgcapsule 6 capsules tid in patients with stage 3 colorectal cancer who underwent surgical excision of their primary tumor
Detailed Description:
The investigational new drug MB-6 in the proposed clinical trial is to be used as an adjuvant therapy for metastatic colorectal cancer patients All of six extracts have been used in human with a long history and many literatures reported the medicinal use either individually or as ingredients of formulations MB-6 may provide its therapeutic benefits via inhibition of tumor induction or enhancing the efficacy of chemotherapy in colorectal cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None